µÏÍþ¹ú¼Ê











   
   
  
 
   
 
    
  µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê  
 
    
 
     

      
      
      
     
 
     

      
     
 
     
 
      

       
       ¼ò
       ¤™
      
 
      
 
       
     
        
  • ¼ò
    •  
        
  • ·±
    •  
        
  • EN
    •  
       
 
      
 
     
 
      
    
 
    
 
      
    
 
   
 
    
   
 
    
 
     
 
       
       
  
      
 
       
 
        
 
         
         
       
 
      
 
     
 
    
 
   
 
    
    
    
  
 
  
 
   
 
   
 
    
 
     ¤œ 
     
 
      

       Ïà¹ØÁ´½Ó
      
 
      
 
       
     
        
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
    •  
       
 
      
 
     
 
    
 
   
 
  
 
   
   
   
  
 
    
   
 
    
 
     

      ÐÂÎÅ·¢²¼
     
 
     

      Press Release
     
 
    
 
   
 
  
 
   
   
  
 
   
 
     
    
 
     Ê×Ò³
      >  
     ÐÂÎÅÖÐÐÄ
      >  ÐÂÎÅ·¢²¼ 
      
    
 
   
 
  
 
   
  

     










  

    

      

        
Ê¥ÂÞÀ³?×îлúÖÆÑо¿ÓÚ¡¶¹ú¼ÊÃâÒßµÏÍþ¹ú¼ÊÀíѧ¡··¢²¼£¬Ö¤Êµ¾ßÓÐDZÔÚÐÄѪ¹Ü±£»¤×÷ÓÃ

        

          
          ·¢²¼ÈÕÆÚ£º2025/11/05
          

            ×ÖºÅ
            
            
            
          

        

        
        

          
½üÈÕ£¬±±¾©´óѧÈËÃñÒ½ÔºÉöÄÚ¿ÆÍŶÓÔÚ¡¶¹ú¼ÊÃâÒßµÏÍþ¹ú¼ÊÀíѧ¡·£¨International Immunopharmacology£¬IF:4.7£©ÔÓÖ¾ÉÏ·¢±íÁËһƪÓйصÏÍþÖƵÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄ´´ÐµÏÍþ¹ú¼ÊÅàĪɳëÄ£¨ÉÌÆ·Ãû£ºÊ¥ÂÞÀ³?£©µÄ»úÖÆÑо¿£¬½ÒʾÁËÊ¥ÂÞÀ³?¾ßÓÐÐÄѪ¹Ü±£»¤×÷Óã¬ÆäÄܹ»Í¨¹ýÒÖÖÆ´Ùºìϸ°ûÉú³ÉËØÊÜÌ壨EPOR£©-CD131Òì¶þ¾ÛÌåµÄÐγÉ£¬×è¶ÏJAK2/STAT3ÐźÅͨ·¼¤»î£¬´Ó¶ø¸ÄÉÆÁòËáßÅßá·Ó£¨IS£¬ÂýÐÔÉöÔಡµÄÒ»Öֹؼü¶¾ËØ£©ÓÕµ¼µÄÐļ¡Ï¸°û·Ê´ó¡£
Õâ²»½öΪÁÙ´²Ñо¿ÖÐËù¹Û²ìµ½µÄÊ¥ÂÞÀ³?Ïà¶Ô½ÏµÍµÄÐÄѪ¹Ü²»Á¼Ê¼þ·¢ÉúÂÊÌṩÁË»úÖÆÒÀ¾Ý£¬»¹¿ÉÄÜΪÂýÐÔÉöÔಡ£¨CKD£©Ïà¹ØÐÄѪ¹Ü²¢·¢Ö¢ÌṩһÖÖÓÐÇ°¾°µÄÖÎÁƲßÂÔ[1]¡£

ÒÑÖªÐÄѪ¹ÜʼþÊÇCKD»¼ÕßËÀÍöµÄÊ×ÒªÔ­Òò£¬¶øÉöÐÔƶѪÊÇCKD»¼ÕßÐÄѪ¹ÜʼþµÄÖØÒªÖ²¡ÒòËØ¡£Òò´Ë£¬Æ¶ÑªµÄÔçÆÚ¸ÉÔ¤¶ÔÓÚ¸ÄÉÆCKD»¼ÕßµÄÐÄѪ¹Ü½á¾Ö¾ßÓÐÖØÒªÒâÒå¡£
È»¶ø£¬´«Í³ESAÀàµÏÍþ¹ú¼ÊÎïÔÚ¿¹Æ¶ÑªµÄͬʱ»áÔö¼Ó²»Á¼ÐÄѪ¹Üʼþ·çÏÕ¡£ÅàĪɳëÄÊǾßÓÐȫнṹµÄС·Ö×ÓëÄÀ໯ѧµÏÍþ¹ú¼ÊÎ¼ÈÍùµÄ¢óÆÚÁÙ´²Ñо¿Ö¤ÊµÁËÆä²»½öÔÚÁÆЧÉÏ·ÇÁÓÓÚ´«Í³¶ÌЧESA£¬¶øÇÒÐÄѪ¹Ü²»Á¼Ê¼þµÄ·¢ÉúÂʸüµÍ[2,3]¡£
±¾´ÎÑо¿½á¹û±íÃ÷£º
¡ñͨ¹ýH9c2Ðļ¡Ï¸°ûÄ£ÐÍʵÑé·¢ÏÖ£¬Ê¥ÂÞÀ³?ÏÔÖø¼õÇáÁËÁòËáßÅßá·ÓÓÕµ¼µÄÐļ¡Ï¸°û·Ê´ó£¬±íÏÖΪÐļ¡·Ê´ó±êÖ¾Îï[°üÀ¨AÐÍÀûÄÆëÄ£¨ANP£©¡¢BÐÍÀûÄÆëÄ£¨BNP£©ºÍ¦Â-¼¡Çòµ°°×ÖØÁ´£¨¦Â-MHC£©]±í´ïµÄÒÖÖÆ¡¢Ï¸°û±íÃæ»ýµÄ¼õÉÙÒÔ¼°Ï¸°û¹Ç¼Ü×éÖ¯µÄ¸ÄÉÆ£¨P < 0.05£©¡£
¡ñÊ¥ÂÞÀ³?Éϵ÷ÁËEPORµÄ±í´ï£¬Í¬Ê±ÒÖÖÆÁËCD131µÄ±í´ïºÍJAK2/STAT3ÐźÅͨ·µÄ¼¤»î¡£¹²ÃâÒß³Áµí·ÖÎöÏÔʾÅàĪɳëÄÒÖÖÆÁËEPOR-CD131Òì¶þ¾ÛÌåµÄÐγɡ£¹¦ÄÜÍì¾ÈʵÑé±íÃ÷£¬CD131¼¤¶¯¼ÁARA290»òSTAT3¼¤»î¼ÁColivelin¿ÉÄæתÅàĪɳëĵÄÐÄÔà±£»¤×÷Ó㬶øÁªºÏʹÓÃARA290ºÍSTAT3ÒÖÖƼÁStatticÔò²¿·Ö»Ö¸´ÁËÆ俹·Ê´ó»îÐÔ¡£ÕâЩ·¢ÏÖÌáʾÁËÅàĪɳëÄ¿Éͨ¹ýÒÖÖÆCD131ºÍSTAT3¶ø·¢»ÓÐļ¡±£»¤×÷Óá£
ÕûÌå¶øÑÔ£¬¸ÃÑо¿Ö¤Ã÷ÁËÊ¥ÂÞÀ³?Äܹ»Í¨¹ýÒÖÖÆCD131±í´ï¡¢×è¶ÏEPOR-CD131Òì¶þ¾ÛÌåµÄÐγÉ£¬½ø¶ø×è¶ÏJAK2/STAT3ͨ·µÄ¼¤»î£¬´Ó¶øÓÐЧ»º½âÁòËáßÅßá·ÓÓÕµ¼µÄÐļ¡Ï¸°û·Ê´ó£¬½ÒʾÁËÒ»ÖÖеÄÐÄÔà±£»¤»úÖÆ¡£


ÖµµÃ×¢ÒâµÄÊÇ£¬Ê¥ÂÞÀ³?¶ÀÌصĻúÖÆ¡ª¡ªÍ¨¹ýµ÷½ÚCD131ÒÀÀµµÄÒì¶þ¾ÛÌ廯¶ø·Ç¾­µäµÄEPOÐźÅͨ·£¬²»½öÓÐÖúÓÚ±ÜÃâÓëEPOÐźÅͨ·Ïà¹ØµÄÐÄѪ¹Ü·çÏÕ£¬Í¬Ê±»¹¸³ÓèÁËÖ±½ÓµÄÐÄÔà±£»¤×÷Óá£ÕâΪÅàĪɳëÄDZÔڵݲȫÐÔÓÅÊÆ£¬°üÀ¨¼õÉÙÐÄѪ¹Ü²»Á¼Ê¼þ£¬ÒÔ¼°Æä¶ÀÌصÄÐÄÔà±£»¤ÌØÐÔ£¬ÌṩÁËÓÐÁ¦µÄ»úÖÆÒÀ¾Ý¡£Ëæ×ÅÅàĪɳëÄÁÙ´²Ó¦ÓõÄÈÕÒæ¹ã·º£¬»¹Ðè½øÒ»²½ÔÚ¶¯ÎïʵÑéºÍCKDÈËȺÖÐÑéÖ¤ÆäÐÄѪ¹Ü»ñÒæ»úÖÆ¡£

²Î¿¼ÎÄÏ×£º
1.Zhang X, Li S, Lin T,et al.Pegmolesatide ameliorates indoxyl sulfate-induced cardiomyocyte hypertrophy through modulating the EPOR-CD131-dependent JAK2/STAT3 signaling pathway.Int Immunopharmacol. 2025 Oct 14;167:115643.
2.Xie J, Yang A, Qiu H,et al. Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD.Kidney Int Rep. 2024 Dec 6;10(3):720-729.
3.Zhang P, Jiang Y, Xu C,et al.Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial.EClinicalMedicine. 2023 Oct 28;65:102273.

¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê
µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀÉ­µÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁÄ¿Ç°£¬¹«Ë¾ÔÚÖйú²úÉúÏúÊÛÊÕÈëµÄ´´ÐµÏÍþ¹ú¼Ê¹²7¿î£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖƵÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖƵÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£
ÃâÔðÉùÃ÷
±¾ÎĽö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍƼö¡£±¾ÎÄÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£
Ç°Õ°ÐÔ˵Ã÷
±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£

          
        

        
      

    

    
  





 
  
 
   
  

   
  
 
   
    
  
 





¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿